Tag: IXC
Invex Therapeutics in strong position to launch Presendin trials
Invex Therapeutics (ASX: IXC) has confirmed its strong financial position as it gets set to commence recruitment for phase three clinical trials of lead drug Presendin on patients with newly diagnosed...
Invex Therapeutics approved to start Presendin phase three clinical trial in Australia
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has been given the green light to start its EVOLVE phase three clinical trial in Australia on patients with idiopathic intracrani...
Invex Therapeutics gains UK regulatory approval for clinical trial of Presendin to treat idiopathic intracranial hypertension
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has received regulatory approval to commence an EVOLVE phase three clinical trial in the United Kingdom for patients with idiopat...
Invex Therapeutics continues preparation ahead of IIH EVOLVE phase three clinical trial
Invex Therapeutics (ASX: IXC) is continuing to advance preparations for the launch of its global IIH EVOLVE phase three clinical trial, which aims to determine safety and efficacy of its drug Presendi...
Invex Therapeutics makes progress ahead of IIH EVOLVE phase three clinical trial
Invex Therapeutics (ASX: IXC) is making strong progress in the preparations for its IIH EVOLVE phase three clinical trial, which aims to achieve global registration of the drug Presendin to treat idio...
Invex Therapeutics receives tax rebate for neurological drug research
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has announced it has received about £100,000 (A$186,000) in a research and development tax rebate from the UK government for the ...
Invex Therapeutics chases global registration of Presendin to treat idiopathic intracranial hypertension
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has confirmed it will proceed with a phase III clinical trial to achieve global registration of lead drug Presendin in the treatm...
Invex Therapeutics reports busy quarter in Presendin development
Clinical stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has reported strong progress made over the September quarter in the development and commercialisation of its drug Presendin for n...
Invex Therapeutics signs major collaboration with Peptron
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has signed a major long-term collaboration and manufacturing agreement with Korean-listed Peptron (KOSDAQ: 087010) in relation to...
Invex Therapeutics collars European patent for elevated intracranial pressure treatment
Invex Therapeutics (ASX: IXC) has collared the European patent for its elevated intracranial pressure (ICP) treatment, Exenatide – protecting this intellectual property in the region and the United St...
Invex Therapeutics closes busy quarter of development on Presendin for idiopathic intracranial hypertension
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has reported a busy quarter focused on the development and commercialisation of Presendin for neurological conditions relating to...
Invex Therapeutics receives US FDA feedback on planned Presendin trial targeting idiopathic intracranial hypertension
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has received written feedback from the US Food and Drug Administration’s (FDA) Division of Neurology relating to the proposed des...
Invex Therapeutics narrows its search for preferred CMO to manufacture commercial quantities of Presendin
Biopharmaceutical company Invex Therapeutics (ASX: IXC) has identified several preferred formulation candidates and narrowed its search for a contract manufacturing organisation (CMO) that will manufa...
Invex Therapeutics granted FDA meeting to advance Presendin phase III trial for treating idiopathic intracranial hypertension
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has been granted a meeting with the US Food and Drug Administration to discuss the planned development pathway for its lead drug ...
Invex Therapeutics files for pre-IND meeting with US FDA regarding Presendin™ trial in IIH sufferers
Invex Therapeutics’ (ASX: IXC) has filed a pre-investigational new drug application with the United States Food and Drug Administration for the proposed phase III trial evaluating its drug Presendin i...
Invex Therapeutics appoints biotech expert Dr Megan Baldwin to its board
Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has welcomed seasoned drug development expert Dr Megan Baldwin to the board as an independent non-executive director, effective t...
Invex Therapeutics pushes on with phase three trial design to repurpose drug for brain disorder
Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment.
The biopharmaceuti...
Invex Therapeutics raises $26 million as it plans for Phase 3 clinical trial
Two days since publishing its Phase 2 clinical trial results and announcing “clear evidence” that its Exeatide drug is effective at reducing intracranial pressure in Idiopathic Intracranial Hypertensi...
Invex Therapeutics aims to repurpose a diabetic drug for brain disorders
Biopharmaceutical company Invex Therapeutics is planning to make its ASX debut this week under the ticker code “IXC” with ambitions to repurpose an approved diabetes drug for some neurological conditi...
